CASK and prostate cancer: Although this claim awaited further validation on larger sizes of samples, CASK dysregulated levels might prove valuable as prognostic markers, especially as CASK overexpression seemed to be strongly associated with the poor prognosis in both metastatic breast and prostate cancers.